South Korean Obesity Drug Market Approaches $1.44 Billion Amid Safety Concerns
South Korea’s obesity drug market is nearing $1.44 billion in annual sales, but regulators have issued warnings regarding potential vision-loss risks amid…

The South Korean market for GLP-1 receptor agonist obesity treatments is projected to reach approximately $1.44 billion in annual revenue by the end of the year. Data indicates that the market grew from $81 million in the first quarter of last year to $403 million in the second quarter of this year, driven largely by the introduction of high-efficacy injectable medications. Currently, one dominant product accounts for roughly 75% of the total market share, with other competitors and domestic manufacturers expected to increase their presence in the coming months.
Institutional expansion continues to track with this market growth. A major domestic contract development and manufacturing organization recently completed a $1.95 billion capital increase to acquire international peptide production capabilities, signaling long-term investment in the global obesity drug supply chain. Despite this commercial momentum, the rapid expansion has outpaced clinical oversight and patient education protocols.
Regulatory authorities in both the United States and Regulatory authorities in both the United States and South Korea have issued safety warnings regarding a rare but serious risk of non-arteritic anterior ischemic optic neuropathy (NAION), a condition that can lead to permanent vision loss. Health officials have confirmed at least one suspected case of NAION in South Korea, prompting the distribution of safety advisories to medical practitioners.
Reports suggest that the widespread use of these drugs for cosmetic weight loss has led to inconsistent clinical practices. Patients have reported receiving prescriptions without adequate counseling on potential side effects or contraindications, often relying on social media for health information rather than medical professionals. Pharmaceutical manufacturers have responded by stating they are monitoring ocular adverse event data and will comply with regulatory guidance to ensure that both healthcare providers and patients are appropriately informed. The discrepancy between rapid market adoption and the quality of patient risk communication remains a significant governance challenge for healthcare providers and regulators.
More stories
- Dietitians advise small swaps for plant-based eating
- TikTok dementia videos mislead in 66.4% of sample, researchers say
- Aberdeen Royal Infirmary faces police inquiry call over 19 deaths
- Bariatric surgery group loses 28.2% after GLP-1 use
- TOFA boosts mouse energy use 18% while preserving muscle
- ICO probes NHS therapy notes accessible to up to 140,000 staff
- PFOS levels track 93% higher aggressive breast cancer rate
- Fructose may weaken ovarian cancer cell bonds after chemotherapy
- VO2 max gives exercisers a clearer longevity signal now
- Smart ring monitors sweat biomarkers without daily exercise
Latest news
- David Parr House to honor Victorian art-workman with blue plaque
- Iran's attacks hit 25 tankers near Strait of Hormuz
- FCC approves prison cellphone jamming despite 2.5-mile warning
- Russia strikes Ukraine as Odesa faces electricity strain
- Bahrain reports two injuries after Iranian aerial attacks
- Congress tests Black Democrats' growing policy influence
- Baltic responders fight Sparta II fire after drone strike
- Europe faces attribution gap after 16 cyber, physical incidents

